Olivia Vizier

Translating ‘nature’s cues’ into breakthrough immunotherapies

Discover how Cue Biopharma harnesses the curative potential of the body’s intrinsic immune system to develop treatments for oncology and autoimmune diseases. Here, Anish Suri, Chief Scientific Officer of Cue Biopharma, explains how its platforms and biologics are designed to selectively modulate disease-specific T cells to restore immune balance, aiming to improve efficacy and minimise

Translating ‘nature’s cues’ into breakthrough immunotherapies Read More »

Teaching Tolerance to Address Autoimmune Diseases

The traditional approach to treating autoimmune disease has relied on ways to suppress the immune system. COUR Pharmaceuticals is developing first-in-class therapies that instead seek to reprogram the immune system to create antigen-specific tolerance. We spoke to COUR CEO John Puisis and COUR Vice President of Research Adam Elhofy, about how the company’s immune-modifying nanoparticles

Teaching Tolerance to Address Autoimmune Diseases Read More »

Biotech2050podcast

Transforming Gene Therapy: Exclusive Insights from Zandy Forbes, President & CEO of MeiraGTx

Zandy Forbes, Founder, President, and CEO of MeiraGTx, joins host Rahul Chaturvedi in this compelling episode. Zandy shares her inspiring journey from academia, where she developed a deep interest in molecular biology and genetics, to her significant role in biotech investing, and eventually leading a groundbreaking gene therapy company

Transforming Gene Therapy: Exclusive Insights from Zandy Forbes, President & CEO of MeiraGTx Read More »

empowered

New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia Pharma

Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues.

New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia Pharma Read More »

Cell Gene Podcast

Developing an mRNA Therapy for DMD with Elixirgen Therapeutics’ Aki Ko on Apple Podcasts

Elixirgen Therapeutics’ Aki Ko joins Erin Harris to detail the company’s Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.

Developing an mRNA Therapy for DMD with Elixirgen Therapeutics’ Aki Ko on Apple Podcasts Read More »

Biotech TV

In humanized mouse models, Tessera is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company’s gene writing platform and programs more broadly.

In humanized mouse models, Tessera is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease Read More »

Scrip_Domain

Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies

Aphaia Pharma, a Swiss biotech, is developing an oral glucose formulation. This aims to restore endogenous signaling mechanisms and metabolic homeostasis in people with obesity, with the goal of mimicking the metabolic effects of bypass surgery without the adverse effects. Its lead drug candidate is currently in a Phase II proof-of-concept study in individuals with

Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies Read More »

BioProcessOnline

New Apps For AI in mRNA With Anima Biotech’s Yochi Slonim

From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired

New Apps For AI in mRNA With Anima Biotech’s Yochi Slonim Read More »